Encycle Therapeutics

Encycle is a private biotechnology company. The company owns an advanced biotechnology platform capable of rapidly synthesizing novel macrocyclic peptide drugs. Macrocyclic peptides possess unique physicochemical properties and have the potential to be developed into a new generation of drugs, currently attracting widespread attention in the pharmaceutical industry.Encycle has collaborated with several pharmaceutical companies to develop a macrocyclic peptide screening platform, laying the foundation for peptide drug research and development. Additionally, the company is developing oral biologics based on Smad ubiquitination regulatory factor 2 (Smurf2).